Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Summary

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Timeline

Start

2024-12-19

Primary completion

2027-09

Completion

2027-12

Publications

• Aksentijevic D, Sedej S, Fauconnier J, Paillard M, Abdellatif M, Streckfuss-Bomeke K, Ventura-Clapier R, van der Velden J, de Boer RA, Bertero E, Dudek J, Sequeira V, Maack C. Mechano-energetic uncoupling in heart failure. Nat Rev Cardiol. 2025 Oct;22(10):773-797. doi: 10.1038/s41569-025-01167-6. Epub 2025 Jun 22.

Drugs

Indications